Baxter Healthcare Corporation received marketing authorization for a generic Intramuscular Diazepam solution on July 28, 2026, introducing additional pricing pressure in the Emergency Medical sector. This approval expands supply chains for critical emergency sedatives but likely poses a formidable threat to existing brand-name competitors.